These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks identifies ANI Pharmaceuticals and Regeneron as potential earnings-surprise candidates, with positive Earnings ESPs of 6.45% and 0.23%, respectively; both carry a Zacks Rank of #3 (Hold). ANI’s $2.31 Most Accurate Estimate compares with a $2.17 consensus ahead of its November 6, 2026 report, while Regeneron’s estimate is $15.96 versus $15.93 consensus ahead of its October 30 report. These are estimate-based signals, not reported earnings results; Zacks says its combination of a #3-or-better rank and positive ESP produced positive surprises 70% of the time in its analysis.

Analysis

This is a revisions-screen signal, not evidence of improving business fundamentals. ANIP’s wider estimate gap makes it the more interesting event setup, but the gap may already be reflected in price and says nothing by itself about the durability or quality of earnings. REGN’s near-zero gap is too small to support a meaningful directional inference. The cited historical hit rate and return backtest are vendor claims; without methodology, sample construction, and transaction costs, they should not be treated as expected returns.

For the next several weeks, the key variable is not merely whether EPS clears consensus, but whether the result changes forward expectations enough to outweigh any pre-report run-up and implied volatility. A headline beat with unchanged or weaker guidance could still sell off; a miss paired with resilient forward commentary could be absorbed. No company-specific operating drivers or valuation context are supplied, so there is no grounded basis here for a fundamental long/short or a sector read-through. The contrarian point: a positive ESP is a relative estimate-revision indicator, not a reliable measure of surprise magnitude or post-earnings upside.

Key Decisions for Investors

• ANIP: place on an event watchlist, not an unconditional long. Before taking risk, verify the latest estimate revision dates, recent price move, consensus dispersion, and options-implied move; the larger estimate gap is the stronger signal of the two, but not yet an attractive risk/reward on its own.
• REGN: no directional trade from a +0.23% estimate gap. Reassess only if meaningful estimate revisions, company guidance, or other independently verifiable operating information changes the setup.
• If ANIP’s implied move is modest relative to comparable historical earnings moves and the share price has not already repriced, consider a small, defined-risk call spread rather than outright calls; otherwise stand aside. Avoid the position if implied volatility is elevated or the stock rallies materially into the report.
• Falsification: an EPS miss, weaker forward guidance, or a post-report decline despite a beat would undermine the positive-surprise thesis. For any options trade, cap loss at premium and reassess after the report rather than assuming a beat translates into durable upside.